U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07539818) titled 'Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML' on April 13.
Brief Summary: This is a prospective, multicenter, randomized, open-label, phase III trial evaluating the efficacy and safety of azacitidine plus venetoclax versus azacitidine alone as maintenance therapy in patients with acute myeloid leukemia (AML) who have achieved first complete remission (CR) or CR with incomplete count recovery (CRi) after induction and consolidation. Eligible patients aged 14 to 74 years are randomized 1:1 to receive either azacitidine 50 mg/m²/day on days 1-5 every 6 weeks for up to 12 cycles, or the same azacitidine reg...